Coagulopathy and increased bleeding risk that occurs secondary to renal failure is often treated with DDAVP rather than blood component therapy (i.e., administering platelets or fresh frozen plasma (FFP)).
InsideSurgery Medical Information Blog
Details of surgical procedures, pathophysiology, signs and symptoms, and treatment of medical diseases,medical and surgical eponyms, and surgeons and surgery in the news
Coagulopathy and increased bleeding risk that occurs secondary to renal failure is often treated with DDAVP rather than blood component therapy (i.e., administering platelets or fresh frozen plasma (FFP)).
Leave a Reply